on BioNxt Solutions Inc. (CVE:BNXT)
BioNxt Solutions Delays 2024 Annual Financial Statement Filing
BioNxt Solutions Inc., based in Vancouver, has announced a delay in filing its annual financial statements for the year ending December 31, 2024. The company cites delays in obtaining necessary financial information as the reason for not meeting the April 30, 2025 deadline. Efforts are underway to complete the filings by June 28, 2025.
A management cease trade order (MCTO) has been applied, restricting trading activities for the CEO and CFO until the filings are submitted. This MCTO requires completion by June 30, 2025. BioNxt plans to follow Alternative Information Guidelines to keep investors informed.
The company ensures no undisclosed material information exists, while affirming its commitment to enhancing healthcare through innovative solutions in drug delivery and pharmaceutical developments.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all BioNxt Solutions Inc. news